Comparative effectiveness of oral diabetes drug combinations in reducing glycosylated hemoglobin

Journal of Comparative Effectiveness Research

Volumn 3, Issue 1, 2014, Pages 29-39

  Flory, James H ^a   Small, Dylan S ^b   Cassano, Patricia A ^a   Brillon, David J ^c   Mushlin, Alvin I ^a   Hennessy, Sean ^d  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

biomarker; combination therapy; comparative effectiveness; diabetes; HbA1c

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; HEMOGLOBIN A1C; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADULT; AGED; ARTICLE; BODY MASS; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENDER; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADMINISTRATION, ORAL; AGE FACTORS; AGED; BODY MASS INDEX; COMPARATIVE EFFECTIVENESS RESEARCH; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEX FACTORS;

EID: 84890937438     PISSN: 20426305     EISSN: 20426313     Source Type: Journal    
DOI: 10.2217/cer.13.87     Document Type: Article

References (22)

1. Hiatt WR, Kaul S, Smith RJ. The cardiovascular safety of diabetes drugs -insights from the rosiglitazone experience. N. Engl. J. Med. 369(14), 1285-1287 (2013).
2. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N. Engl. J. Med. 329(14), 977-986 (1993).
3. Bolen S, Vassy J, Feldman L et al. Comparative effectiveness and safety of oral diabetes medications for adults with Type 2 diabetes. Agency for Healthcare Research and Quality, Rockville, MD, USA (2007).
4. Qaseem A, Humphrey LL, Sweet DE et al. Oral pharmacologic treatment of Type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann. Intern. Med. 156(3), 218-231 (2012).
5. Esposito K, Chiodini P, Bellastella G, Maiorino MI, Giugliano D. Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in Type 2 diabetes: systematic review of 218 randomized controlled trials with 78,945 patients. Diabetes Obes. Metab. 14(3), 228-233 (2012).
6. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 355(23), 2427-2443 (2006).
7. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in Type 2 diabetes. JAMA 303(14), 1410-1418 (2010).
8. Nathan DM, Buse JB, Kahn SE et al. Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care 36(8), 2254-2261 (2013).
9. Jones TA, Sautter M, Van Gaal LF, Jones NP. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with Type 2 diabetes. Diabetes Obes. Metab. 5(3), 163-170 (2003).
10. Blak BT, Thompson M, Dattani H, Bourke A. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates. Inform. Prim. Care 19(4), 251-255 (2011).
11. Hall GC, McMahon AD, Dain MP, Home PD. A comparison of duration of first prescribed insulin therapy in uncontrolled Type 2 diabetes. Diabetes Res. Clin. Pract. 94(3), 442-448 (2011).
12. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA(1c), analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care 25(2), 275-278 (2002).
13. National Collaborating Centre for Chronic Conditions. Type 2 Diabetes: National clinical guideline for management in primary and secondary care (update). Royal College of Physicians, London, UK (2008).
14. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat. Med. 28(25), 3083-3107 (2009).
15. Bailey CJ. Interpreting adverse signals in diabetes drug development programs. Diabetes Care 36(7), 2098-2106 (2013).
16. Herrington WG, Levy JB. Metformin: effective and safe in renal disease? Int. Urol. Nephrol. 40(2), 411-417 (2008).
17. Cariou B, Charbonnel B, Staels B. Thiazolidinediones and PPAR? agonists: time for a reassessment. Trends Endocrinol. Metab. 23(5), 205-215 (2012).
18. Azoulay L, Yin H, Filion KB et al. The use of pioglitazone and the risk of bladder cancer in people with Type 2 diabetes: nested case-control study. BMJ 344, e3645 (2012).
19. Schernthaner G, Currie CJ, Schernthaner GH. Do we still need pioglitazone for the treatment of Type 2 diabetes? A risk-benefit critique in 2013. Diabetes Care 36(Suppl. 2), S155-S161 (2013).
20. Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of Type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 33(2), 428-433 (2010).
21. American Diabetes Association. Standards of medical care in diabetes -2013. Diabetes Care 36(Suppl. 1), S11-S66 (2013).
22. Garber AJ, Abrahamson MJ, Barzilay JI et al. AACE comprehensive diabetes management algorithm 2013. Endocr. Pract. 19(2), 327-336 (2013).